(Q50561727)

15 March 2018

editorial

0 references

title

Anti-inflammatory strategies in the treatment of schizophrenia. (English)

1 reference

15 March 2018

0 references

Chittaranjan Andrade

1

1 reference

15 March 2018

language of work or name

English

0 references

publication date

1 October 2015

1 reference

15 March 2018

Expert Review of Clinical Pharmacology

published in

1 reference

15 March 2018

volume

9

1 reference

15 March 2018

issue

2

1 reference

15 March 2018

page(s)

161-163

1 reference

15 March 2018

The neuroimmunology of schizophrenia

cites work

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1095086

Inflammation and the two-hit hypothesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1095086

The cytokine model of schizophrenia: emerging therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1095086

Inflammatory cytokine network in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1095086

Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1095086

Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1095086

Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1095086

Advances in monitoring of aspirin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1095086

Too good to be true? Aspirin and schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1095086

Celecoxib augmentation of continuously ill patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1095086

Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1095086

Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1095086

Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1095086

Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1095086

Nonsteroidal anti-inflammatory drugs and 5-HT₃ serotonin receptor antagonists as innovative antipsychotic augmentation treatments for schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1095086

Effect of epigallocatechin gallate supplementation in schizophrenia and bipolar disorder: an 8-week, randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1095086

A review of anti-inflammatory agents for symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1095086

A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1095086

10.1586/17512433.2016.1095086

21 January 2018

Identifiers

DOI

1 reference

15 March 2018

PubMed ID

26427750

1 reference

15 March 2018